Abstract
A fundamental problem in cancer research is identification of the cells responsible for tumor formation. The latest field of cancer research has revealed the existence and role of cancer stem cells (CSCs). These findings support the idea that malignancies originate from a small fraction of cancer cells that show self-renewal and multi- or pluripotency. Identification of this CSC population has important implications for the management of cancer patients, including diagnostic and predictive laboratory assays as well as novel therapeutic strategies that specifically target CSCs. In this study, we investigated the growth rates of CSC populations for comparison with cancer cell lines. To construct the growth curves, blood-derived CSCs were isolated from patients with breast, colon, or lung cancer and cultured in vitro. Quantitative real-time PCR was then performed to identify CSCs in the samples. We found that CSCs did not follow the common pattern of a typical growth curve of mammalian cells in contrast to the cancer cell lines. This observation of rapidly growing CSCs indicates their involvement in tumor formation.
Keywords: Cancer stem cells, growth curves, Nanog, Oct3/4, Sox2.
Current Stem Cell Research & Therapy
Title:Comparison of the Growth Curves of Cancer Cells and Cancer Stem Cells
Volume: 9 Issue: 2
Author(s): Maria Toloudi, Eleni Ioannou, Marina Chatziioannou, Panagiotis Apostolou, Christos Kiritsis, Stella Manta, Dimitrios Komiotis and Ioannis Papasotiriou
Affiliation:
Keywords: Cancer stem cells, growth curves, Nanog, Oct3/4, Sox2.
Abstract: A fundamental problem in cancer research is identification of the cells responsible for tumor formation. The latest field of cancer research has revealed the existence and role of cancer stem cells (CSCs). These findings support the idea that malignancies originate from a small fraction of cancer cells that show self-renewal and multi- or pluripotency. Identification of this CSC population has important implications for the management of cancer patients, including diagnostic and predictive laboratory assays as well as novel therapeutic strategies that specifically target CSCs. In this study, we investigated the growth rates of CSC populations for comparison with cancer cell lines. To construct the growth curves, blood-derived CSCs were isolated from patients with breast, colon, or lung cancer and cultured in vitro. Quantitative real-time PCR was then performed to identify CSCs in the samples. We found that CSCs did not follow the common pattern of a typical growth curve of mammalian cells in contrast to the cancer cell lines. This observation of rapidly growing CSCs indicates their involvement in tumor formation.
Export Options
About this article
Cite this article as:
Toloudi Maria, Ioannou Eleni, Chatziioannou Marina, Apostolou Panagiotis, Kiritsis Christos, Manta Stella, Komiotis Dimitrios and Papasotiriou Ioannis, Comparison of the Growth Curves of Cancer Cells and Cancer Stem Cells, Current Stem Cell Research & Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574888X0902140121163539
DOI https://dx.doi.org/10.2174/1574888X0902140121163539 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Medicinal Chemistry Drug Repurposing in Chemical Genomics: Can We Learn from the Past to Improve the Future?
Current Topics in Medicinal Chemistry PPARγ Agonists in Combination Cancer Therapies
Current Cancer Drug Targets Human-Derived Organ-on-a-Chip for Personalized Drug Development
Current Pharmaceutical Design Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Emerging Therapeutic Agents for Cervical Cancer
Recent Patents on Anti-Cancer Drug Discovery Screening of Potential Plant Compounds as Survivin Inhibitors and its Anti-Cancer Efficacy by Molecular Docking
Current Enzyme Inhibition Acute and Sub-chronic Toxicity Analyses of Hot-Water Extract of Isaria japonica from Silkworm (Bombyx mori) Pupae
Current Traditional Medicine Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Mesenchymal Stromal Cells Uptake and Release Paclitaxel without Reducing its Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Betulinic Acid Kills Colon Cancer Stem Cells
Current Stem Cell Research & Therapy <i>In Silico</i> Anticancer Evaluation, Molecular Docking and Pharmacophore Modeling of Flavonoids against Various Cancer Targets
Letters in Drug Design & Discovery Tomographic Imaging Methods and Gated Technique in Nuclear Cardiology: A Review on Current Status and Future Developments
Recent Patents on Medical Imaging Characterization and in vitro Cytotoxicity Evaluation of Meloxicam Loaded PEGylated Mixed Micelles Fabricated Using Quality by Design Approach
Drug Delivery Letters Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?
Current Cancer Drug Targets